Immediate Impact
66 standout
Citing Papers
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
2025 Standout
NLRP3 inflammasome in neuroinflammation and central nervous system diseases
2025 Standout
Works of Janice Smith being referenced
Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease
2022
P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer’s Disease
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Janice Smith | 80 | 45 | 40 | 42 | 33 | 240 | |
| Anna Burke | 66 | 94 | 30 | 61 | 26 | 285 | |
| Elias Ghossoub | 96 | 95 | 35 | 24 | 29 | 263 | |
| Mahwish Adnan | 30 | 61 | 32 | 39 | 22 | 264 | |
| Raj K. Kalapatapu | 26 | 54 | 34 | 46 | 29 | 271 | |
| Henning Johannes Drews | 38 | 17 | 71 | 19 | 29 | 233 | |
| Clara Vila‐Castelar | 104 | 133 | 83 | 25 | 33 | 288 | |
| Georgios Seitidis | 32 | 74 | 35 | 19 | 17 | 246 | |
| Murat Gülsün | 40 | 62 | 17 | 29 | 32 | 295 | |
| Eric Cunningham | 35 | 24 | 37 | 18 | 21 | 285 | |
| Pallavi Joshi | 22 | 65 | 20 | 12 | 38 | 268 |
All Works
Login with ORCID to disown or claim papers
Loading papers...